2022
DOI: 10.1016/j.cveq.2021.11.003
|View full text |Cite
|
Sign up to set email alerts
|

Chronic Renal Failure-Causes, Clinical Findings, Treatments and Prognosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
19
0
1

Year Published

2022
2022
2024
2024

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 26 publications
(20 citation statements)
references
References 84 publications
0
19
0
1
Order By: Relevance
“…e majority of individuals with stages I-III are asymptomatic or present moderate symptoms such as fatigue, anorexia, and mild anemia. Disease progression is associated with more severe symptoms such as heart failure, hyperkalemia, gastrointestinal bleeding, and neurological disorders, posing a great threat to the health of patients [4]. Evidence has con rmed the association of the occurrence of chronic renal failure with primary glomerular disease, diabetic nephropathy, immune disease kidney damage, and drug-related kidney damage; besides, the disease progression is accelerated in the presence of infection, insu cient blood circulation, and the use of nephrotoxic drugs [5].…”
Section: Introductionmentioning
confidence: 99%
“…e majority of individuals with stages I-III are asymptomatic or present moderate symptoms such as fatigue, anorexia, and mild anemia. Disease progression is associated with more severe symptoms such as heart failure, hyperkalemia, gastrointestinal bleeding, and neurological disorders, posing a great threat to the health of patients [4]. Evidence has con rmed the association of the occurrence of chronic renal failure with primary glomerular disease, diabetic nephropathy, immune disease kidney damage, and drug-related kidney damage; besides, the disease progression is accelerated in the presence of infection, insu cient blood circulation, and the use of nephrotoxic drugs [5].…”
Section: Introductionmentioning
confidence: 99%
“…Edema is known to be caused primarily due to cardiovascular (especially lymphatic) [ 20 ] and/or renal dysfunction. [ 21 ] Because VEGFR inhibition is known to influence vasculature, we visualized blood vessels using NBT/BCIP staining and lymphatic vessels using prox1 [ 22 ] antibody staining in cabozantinib‐exposed larvae. We found defects in blood and lymphatic vasculature, and a reduction in the expression of the lymphatic vessel marker genes prox1a and sox18 [ 23 ] due to cabozantinib.…”
Section: Discussionmentioning
confidence: 99%
“…The sample size calculation adopted a simple random sampling formula taking α = 0.05 and Z α /2 = 1.96. According to the study of the international incidence of CKD [9], it was estimated that the incidence of CKD was 12%, the error was taken by 5% and the required sample size was calculated to be 203 patients. Additionally, considering that there might be an invalid questionnaire, the required sample size was increased by 15%; thus, a total of 233 patients were selected.…”
Section: Methodsmentioning
confidence: 99%